Product image of Mometaxon (Mometasone Furoate) supplied by GNH India

Mometaxon

Active Ingredient:
Mometasone Furoate
Origin:
EU

Mometaxon (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometaxon, is a potent corticosteroid presented as a topical formulation for skin application. It is used to manage inflammatory skin disorders such as psoriasis, atopic dermatitis, seborrheic dermatitis, contact dermatitis and other related conditions in both adults and children under medical supervision.

GNH India supplies Mometaxon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures product quality, traceability and compliance with Good Distribution Practice throughout the supply chain.

Manufacturer / TM Owner

Hasco-Lek

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mometasone furoate is a topical corticosteroid that reduces inflammation in various dermatoses.

  • Psoriasis: decreases plaque thickness, erythema and scaling.
  • Atopic dermatitis (eczema): relieves itching, redness and inflammation.
  • Seborrheic dermatitis: controls scaling and facial redness.
  • Contact dermatitis: diminishes allergic skin reactions.
  • Nummular eczema: reduces lesion size and pruritus.

How It Works

  • Mometasone furoate binds to intracellular glucocorticoid receptors, altering gene transcription that suppresses pro‑inflammatory cytokine production, inhibits inflammatory cell migration, and reduces edema. This modulation of the immune response leads to decreased skin inflammation and relief of associated symptoms.

Side Effects

Mometasone furoate may cause local and systemic adverse reactions.

Common Side Effects

  • Skin irritation or burning sensation at the application site.
  • Pruritus or mild itching.
  • Dryness or peeling of the treated skin.
  • Acneiform eruptions or folliculitis.

Serious or Rare Side Effects

  • Hypothalamic‑pituitary‑adrenal (HPA) axis suppression with systemic effects.
  • Severe allergic reactions such as angioedema or urticaria.
  • Skin atrophy, telangiectasia or striae formation.
  • Secondary bacterial, fungal or viral skin infections.

Precautions & Warnings

Before using Mometaxon, consider the following precautions.

  • Assess severity: limit use to mild‑moderate conditions and avoid extensive body surface coverage.
  • Use lowest potency: apply the smallest effective amount for the shortest duration.
  • Avoid prolonged use: discontinue after recommended treatment period to prevent skin atrophy.
  • Do not apply to infected or ulcerated skin without medical advice.
  • Avoid occlusion: do not cover treated area with airtight dressings unless directed.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Mometaxon may interact with other agents; monitor accordingly.

Major Interactions (Avoid)

  • Systemic corticosteroids: increased risk of HPA‑axis suppression.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic absorption.
  • Antifungal agents (e.g., azoles): potential additive immunosuppression.
  • Live vaccines: reduced vaccine efficacy due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Antidiabetic drugs: possible hyperglycaemia.
  • Antihistamines: may mask local irritation.
  • Phototherapy: heightened skin sensitivity.
  • Topical antibiotics: risk of combined skin irritation.
  • Systemic immunosuppressants: additive effect on immune function.

Frequently Asked Questions

Mometaxon contains mometasone furoate, a topical corticosteroid indicated for inflammatory skin disorders such as psoriasis, atopic dermatitis (eczema), seborrheic dermatitis, contact dermatitis and other similar conditions where reduction of redness, scaling and itching is required.

Mometasone furoate binds to glucocorticoid receptors inside skin cells, altering gene transcription to suppress pro‑inflammatory cytokines, reduce inflammatory cell migration, and limit edema. This anti‑inflammatory and immunosuppressive action helps calm irritated skin.

The exact amount and frequency of Mometaxon are determined by the prescribing clinician based on the specific skin condition, severity, patient age and treatment area. Patients should follow the prescriber’s instructions and not exceed the recommended duration.

Safety data for mometasone furoate in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers should weigh potential benefits against risks before prescribing to pregnant or nursing individuals.

To request Mometaxon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometaxon (mometasone furoate) is a high‑potency class I/II corticosteroid, offering strong anti‑inflammatory effects with a relatively low risk of systemic absorption when used as directed. Compared with lower‑potency agents such as hydrocortisone, it provides faster symptom control but requires careful monitoring to avoid local side effects.

Store Mometaxon at room temperature, preferably below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture, heat and direct sunlight to maintain product stability.

Mometaxon is applied topically to the affected skin area. The prescribed amount—usually a thin film—should be gently spread on clean, dry skin and gently rubbed in. Hands should be washed before and after application, and the treated area should not be covered with airtight dressings unless instructed by a clinician.

Serious risks include hypothalamic‑pituitary‑adrenal (HPA) axis suppression, severe allergic reactions such as angioedema, skin atrophy or striae with prolonged use, and secondary infections of the skin. Patients should report any unusual symptoms promptly to their healthcare provider.

Mometaxon should be avoided in individuals with known hypersensitivity to mometasone furoate or any formulation excipients, in untreated bacterial, viral or fungal skin infections, and in patients where systemic corticosteroid therapy is contraindicated unless directed by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mometasone Furoate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT